PEPTIDE VACCINES AND DURVALUMAB FOR TREATING MULTIPLE MYELOMA

摘要

The disclosure features, inter alia, combination therapies comprising durvalumab and one or more immunogenic XBP1-, CD138-, and CS1-derived peptides. The therapies herein can be used, e.g., for inducing an immune response in a subject having a blood cancer, and treating a blood cancer such as multiple myeloma, e.g., smoldering multiple myeloma.